Robert Pinke, MD
Ophthalmology · Succasunna, NJNPI 1437155041
Payments from drug & device makers
Across 143 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Glaukos Corporation$644
- AbbVie$478
- Sun Pharmaceutical Industries Inc.$246
- Amgen$175
- Harrow Eye, LLC$170
- plus $762 from 15 others
What the payments were for
- Travel & lodging$120%
- Food & beverage$3,51399%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 35 | $1,069 |
| Glaukos Corporation | 7 | $644 |
| AbbVie(2 entities) | 40 | $478 |
| Sun Pharmaceutical Industries Inc. | 15 | $246 |
| Amgen(2 entities) | 5 | $175 |
| Harrow Eye, LLC | 4 | $170 |
| Sight Sciences, Inc. | 2 | $145 |
| Bausch & Lomb Americas Inc. | 4 | $144 |
| Ocular Therapeutix, Inc. | 6 | $90 |
| Kala Pharmaceuticals, Inc. | 4 | $57 |
| Aerie Pharmaceuticals, Inc. | 3 | $46 |
| Eyevance Pharmaceuticals LLC | 3 | $45 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $43 |
| Tarsus Pharmaceuticals, Inc. | 2 | $39 |
| Novartis | 3 | $39 |
| Oyster Point Pharma, Inc. | 2 | $29 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Dompe US, Inc. | 1 | $19 |
| Johnson & Johnson Vision Care, Inc. | 1 | $16 |
| Omeros Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORA$150
- iStent Trabecular Micro-Bypass System Model iS3$143
- AcrySof IQ PanOptix$132
- OMNI$125
- VEVYE$121
- TEPEZZA$118
- PanOptix$112
How this compares
$3,544 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 71 | $109,354 |
| LumiganBimatoprost | 149 | $95,405 |
| RocklatanNetarsudil Mesylat/Latanoprost | 126 | $56,557 |
| VyzultaLatanoprostene Bunod | 58 | $37,293 |
| XiidraLifitegrast | 36 | $34,552 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 109 | $28,300 |
| Cyclosporine | 38 | $23,741 |
| CombiganBrimonidine Tartrate/Timolol | 35 | $22,174 |
| CequaCyclosporine | 15 | $18,497 |
| Travoprost | 117 | $17,496 |
| RhopressaNetarsudil Mesylate | 40 | $17,105 |
| Timolol Maleate | 256 | $15,668 |
| Alphagan PBrimonidine Tartrate | 27 | $14,037 |
| TyrvayaVarenicline Tartrate | 12 | $11,899 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $478 | $240,970282 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $144 | $82,040108 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $46 | $73,662166 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $246 | $18,49715 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $29 | $11,89912 claims |
| AlconSimbrinza | $1,069 | $6,19218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Succasunna
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.